Alexza Pharmaceuticals Lowered to Neutral at Roth Capital (ALXA)
Alexza Pharmaceuticals (NASDAQ:ALXA) was downgraded by Roth Capital from a “buy” rating to a “neutral” rating in a research note issued on Friday, TheFlyOnTheWall.com reports. They currently have a $5.50 target price on the stock, down from their previous target price of $10.00. Roth Capital’s price target suggests a potential upside of 36.14% from the company’s current price.
Shares of Alexza Pharmaceuticals (NASDAQ:ALXA) traded down 16.87% during mid-day trading on Friday, hitting $4.04. 938,667 shares of the company’s stock traded hands. Alexza Pharmaceuticals has a 52-week low of $3.63 and a 52-week high of $5.93. The stock has a 50-day moving average of $4.69 and a 200-day moving average of $4.6. The company’s market cap is $70.0 million.
Alexza Pharmaceuticals (NASDAQ:ALXA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.33. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.24 million. On average, analysts predict that Alexza Pharmaceuticals will post $-2.35 earnings per share for the current fiscal year.
Alexza Pharmaceuticals, Inc (NASDAQ:ALXA) is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system (CNS) conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.